Aktis Oncology, Inc. (AKTS)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | 7 | 0 | 0 | 1 | 6 | 10 | 15 |
| Operating profit | $m | -75 | -87 | ||||||
| Net profit | $m | - | -47 | -18 | -29 | -44 | -64 | -73 | -94 |
| EPS reported | $ | -1.19 | -1.05 | ||||||
| Operating cashflow per share | $ | -1.22 | -1.09 | ||||||
| Capex per share | $ | 0.18 | 0.13 | ||||||
| FCF per share | $ | -1.40 | -1.22 | ||||||
| Free cash flow | $m | -74 | -85 | ||||||
| Net debt | $m | -227 | -506 | ||||||
| Book value equity | $m | -146 | 485 | ||||||
| Book value per share | $ | -2.78 | 8.76 | ||||||
| Number of shares | m | 52.52 | 55.32 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -8.05 | 2.43 | ||||||
| P/S LTM | x | 181.08 | 116.95 | ||||||
| P/FCF LTM | x | -15.96 | -13.91 | ||||||
| EV/EBITDA LTM | x | -18.73 | -14.80 | ||||||
| EV/Sales LTM | x | 177.05 | 161.93 | ||||||
| Earnings Yield LTM | % | -5.42% | -3.85% | ||||||
| FCF Yield | % | -6.27% | -7.19% | ||||||
| Quality | |||||||||
| ROE | % | +43.61% | -32.35% | ||||||
| ROIC | % | -31.79% | -13.09% | ||||||
| Operating margin | % | -11.50% | -8.13% | ||||||
| Gross margin | % | +100.00% | +81.95% | ||||||
| FCF/Sales | % | -1134.5% | -794.01% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +336.92% | +576.53% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -6.38 | -7.52 | ||||||
| Net Debt/EBITDA | x | 0.43 | 1.18 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | +0.10% | ||||||
| Net debt/Equity | x | 1.55 | -1.04 | ||||||
| Gross debt/equity | x | -0.08 | 0.02 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free